Professor Peter Horby and Professor Martin Landray, chief investigators of the RECOVERY Trial, said ‘In March this year, RECOVERY was established as a randomised clinical trial to test a range of potential drugs for COVID-19, including hydroxycholoroquine.
‘The trial has proceeded at unprecedented speed, enrolling over 11,000 patients from 175 NHS hospitals in the UK. Throughout this time, the independent Data Monitoring Committee has reviewed the emerging data about every two weeks to determine if there is evidence that would be strong enough to affect national and global treatment of COVID-19.
‘On Thursday 4 June, in response to a request from the UK Medicines and Healthcare Products Regulatory Agency (MHRA), the independent Data Monitoring Committee conducted a further review of the data. Last night, the Committee recommended the chief investigators review the unblinded data on the hydroxychloroquine arm of the trial.
‘We have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19. We have therefore decided to stop enrolling participants to the hydroxychloroquine arm of the RECOVERY trial with immediate effect. We are now releasing the preliminary results as they have important implications for patient care and public health.
‘A total of 1542 patients were randomised to hydroxychloroquine and compared with 3132 patients randomised to usual care alone. There was no significant difference in the primary endpoint of 28-day mortality (25.7% hydroxychloroquine vs. 23.5% usual care; hazard ratio 1.11 [95% confidence interval 0.98-1.26]; p=0.10). There was also no evidence of beneficial effects on hospital stay duration or other outcomes.
‘These data convincingly rule out any meaningful mortality benefit of hydroxychloroquine in patients hospitalised with COVID-19. Full results will be made available as soon as possible.
Peter Horby, Professor of Emerging Infectious Diseases and Global Health in the Nuffield Department of Medicine, University of Oxford, and Chief Investigator for the trial, said: ‘Hydroxychloroquine and chloroquine have received a lot of attention and have been used very widely to treat COVID patients despite the absence of any good evidence. The RECOVERY trial has shown that hydroxychloroquine is not an effective treatment in patients hospitalised with COVID-19. Although it is disappointing that this treatment has been shown to be ineffective, it does allow us to focus care and research on more promising drugs.’
Martin Landray, Professor of Medicine and Epidemiology at the Nuffield Department of Population Health, University of Oxford, and Deputy Chief Investigator, said, ‘There has been huge speculation and uncertainty about the role of hydroxychloroquine as a treatment for COVID-19, but an absence of reliable information from large randomised trials. Today’s preliminary results from the RECOVERY trial are quite clear – hydroxychloroquine does not reduce the risk of death among hospitalised patients with this new disease. This result should change medical practice worldwide and demonstrates the importance of large, randomised trials to inform decisions about both the efficacy and the safety of treatments.’
Full details of the study protocol and related materials are available at www.recoverytrial.net
A Universidade de Oxford, do Reino Unido, anunciou ontem que, após a revisão do experimento ''RECOVERY Trial'', conduzido desde março com 11.000 pacientes de 175 hospitais do Sistema de Saúde () do Reino Unido e chefiado pelos professores Peter Horby e Martin Landray, não foram encontradas evidências de que a  e a hidroxicloroquina curem . "Concluímos que não há efeito benéfico da hidroxicloroquina em pacientes hospitalizados com COVID-19. Decidimos, portanto, interromper a inscrição dos participantes no braço da hidroxicloroquina do estudo RECOVERY imediatamente. Agora estamos divulgando os resultados preliminares, pois eles têm implicações importantes para o atendimento ao paciente e para a saúde pública", anunciaram os pesquisadores. 

A posição oficial veio após um pedido da Agência Reguladora de Medicamentos do Reino Unido (MHRA) para que o estudo fosse revisado.

Os professores também explicaram que na comparação entre os pacientes que foram tratados com as substâncias e os que receberam outros medicamentos "não houve diferença significativa no ''endpoint'' primário da mortalidade em 28 dias (25,7% de hidroxicloroquina X 23,5% dos cuidados usuais)". "Estes dados excluem de forma convincente qualquer benefício significativo da mortalidade da hidroxicloroquina em pacientes hospitalizados com COVID-19", enfatizaram.   

'''A polêmica da cloroquina'''

A revista científica '''' divulgou um estudo há cerca de 10 dias com um alerta sobre o perigo de usar os medicamentos, já que eles podem causar ou agravar arritmias cardíacas. No entanto, esta semana a revista publicou uma "retratação", anunciando que não havia como fazer uma reavaliação completa dos dados, o que comprometia a análise, após o que a  anunciou que voltaria a avaliar a cloroquina e a hidroxicloroquina como possíveis medicamentos para tratar pacientes de COVID-19. 

As substâncias têm sido defendidas pelos presidentes Donald Trump, dos Estados Unidos, e Jair Bolsonaro, do Brasil, para tratar doentes de COVID-19, no entanto, em ambos os países, onde os medicamentos estão sendo usados há meses, as mortes têm batido recordes.